Orig3n Inc, a Boston-based biotech company involved in genetics and regenerative medicine research, has acquired Interleukin Genetics CLIA laboratory and its remaining assets, it was reported yesterday.
The acquisition is intended to allow Interleukin Genetics' technology to become a core component of Orig3n's DNA test business.
The automated genotyping lab is completely-licensed for testing in all 50 US states and is capable of processing over one million samples per annum. In addition to the company's technology and its HIPAA and HITECH compliance, Interleukin Genetics also provides Orig3n with its ILUSTRA Inflammation Management Program and its Inherent Health genetic tests for nutritional needs, weight management, heart health, and bone health.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients